Allygen Biologics

Explore the latest insights on Allygen Biologics and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Allygen Biologics’ developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Company Drug

Sinocelltech’s SCT810 Injection Wins NMPA Clearance for Phase I/II Study – Anti‑TFPI Antibody Offers Factor‑Independent Prophylaxis for Hemophilia A and B With or Without Inhibitors

Beijing Sinocelltech Group Ltd. (SHA: 688520) announced that SCT810 Injection has been approved by China's National Medical Products Administration (NMPA) to initiate a Phase I/II clinical study in patients with…

October 13, 2026

Insilico Medicine Nominates ISM9546 as Preclinical Candidate – Oral, Peripherally Restricted VAV1 Molecular Glue Degrader Targets IBD and Rheumatoid Arthritis

October 13, 2026

Lepu Scientech’s MemoCarna Oxide Film Single‑Rivet PFO Occluder Approved for Market Launch by NMPA – Novel Design Targets Residual Shunts in Patent Foramen Ovale Closure

October 13, 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.

Explore Now

Company Deals